-
公开(公告)号：EP3380488A1
公开(公告)日：2018-10-03
申请号：EP16804852.8
申请日：2016-11-23
发明人： POWLESLAND, Alex , CHESTER, Fiona
CPC分类号： C07K4/12 , A61K38/00 , A61K39/0011 , A61K2039/605 , A61P35/00 , C07K7/06 , C07K7/08 , C07K14/7051 , C07K14/70539
摘要： The present invention relates to novel peptides derived from melanoma-associated antigen C2 (MAGEC2), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
-
公开(公告)号：EP3380506A1
公开(公告)日：2018-10-03
申请号：EP16805199.3
申请日：2016-11-23
发明人： POWLESLAND, Alex , CHESTER, Fiona , DELLACRISTINA, Pietro , CHILLAKURI, Chandramouli , SANGANI, Dhaval , HOOD, Graham , LIM, Alfred
CPC分类号： C07K7/06 , C07K7/08 , C07K14/4748 , C07K14/70539
摘要： The present invention relates to novel peptides derived from Cancer/testis antigen family 45 member A1 (CT45A1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
-
公开(公告)号：EP3380115A1
公开(公告)日：2018-10-03
申请号：EP16805189.4
申请日：2016-11-23
发明人： POWLESLAND, Alex , POPA, Alina , CHESTER, Fiona
CPC分类号： C07K7/06 , A61K39/0011 , A61K2039/605 , C07K14/47 , C07K14/7051 , C07K14/70539 , C07K16/2833 , C07K2317/32 , G01N33/564
摘要： The present invention relates to novel peptides derived from piwi-like protein 1 (PIWIL1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
-
公开(公告)号：EP3974443A3
公开(公告)日：2023-01-11
申请号：EP21183259.7
申请日：2016-11-23
发明人： POWLESLAND, Alex , CHESTER, Fiona
摘要： The present invention relates to novel peptides derived from Melanoma-associated antigen B2 (MAGEB2), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
-
公开(公告)号：EP3974443A2
公开(公告)日：2022-03-30
申请号：EP21183259.7
申请日：2016-11-23
发明人： POWLESLAND, Alex , CHESTER, Fiona
摘要： The present invention relates to novel peptides derived from Melanoma-associated antigen B2 (MAGEB2), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
-
6.发明公开
公开(公告)号：EP3380507A1
公开(公告)日：2018-10-03
申请号：EP16805201.7
申请日：2016-11-23
发明人： POWLESLAND, Alex , CHESTER, Fiona
IPC分类号： C07K14/47
CPC分类号： C07K14/4748 , A61K38/00 , A61P35/00 , C07K14/7051 , C07K14/70539
摘要： The present invention relates to novel peptides derived from Sarcoma antigen 1 (SAGE1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
-
公开(公告)号：EP3380502A1
公开(公告)日：2018-10-03
申请号：EP16805193.6
申请日：2016-11-23
发明人： POWLESLAND, Alex , CHESTER, Fiona
CPC分类号： C07K14/4748 , A61K38/00 , C07K7/06 , C07K7/08 , C07K14/7051 , C07K14/70539 , C07K16/30 , C07K2319/00 , G01N33/57492
摘要： The present invention relates to novel peptides derived from Melanoma-associated antigen B2 (MAGEB2), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
-
公开(公告)号：EP3380116A1
公开(公告)日：2018-10-03
申请号：EP16805190.2
申请日：2016-11-23
发明人： POWLESLAND, Alex , CHESTER, Fiona , POPA, Alina
CPC分类号： C12N9/6445 , A61K38/00 , A61K39/0011 , A61K2039/605 , C07K14/7051 , C07K14/70539 , C07K16/40 , C07K19/00 , C07K2319/00 , G01N33/573
摘要： The present invention relates to novel peptides derived from Kallikrein-4 (KLK4), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
-
公开(公告)号：EP3394094A1
公开(公告)日：2018-10-31
申请号：EP16826144.4
申请日：2016-12-22
申请人： Immunocore Limited
发明人： CHESTER, Fiona , KNOX, Andrew Alexander , LOWTHER, Jonathan Patrick , PATEL, Viren Vinubhai , BASTON, Emma Elizabeth , HAGUE, Ruth Martinez
IPC分类号： C07K14/725 , A61K39/00 , C12N5/0783 , A61P35/00 , C07K14/47
CPC分类号： C07K14/7051 , A61K39/0011 , A61K2039/5156 , A61K2039/605 , C07K14/4748 , C12N5/0638
摘要： The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide SLLMWITQC derived from the cancer antigen NY-ESO-1. Said TCRs may comprise mutations within the alpha and/or beta variable domains relative to a native NY-ESO-1 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.018 秒)
